Findings

What do systematic reviews say?

1,266 questions · 1,314 findings · 160 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 309 · 23.5%GRADE not reported 34 · 2.6%Very low 356 · 27.1%Low 393 · 29.9%Moderate 187 · 14.2%High 35 · 2.7%

Nebulized budesonide vs viscous budesonide

Histological improvement (dichotomous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nebulized budesonide vs viscous budesonide

Histological improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Nebulized budesonide vs viscous budesonide

Endoscopic improvement (dichotomous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Corticosteroids vs placebo

Clinical improvement (continuous) · inactive EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 269 participants
Very low

Nebulized budesonide vs viscous budesonide

Endoscopic improvement (continuous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nebulized budesonide vs viscous budesonide

Withdrawals due to adverse events · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Viaskin milk patch vs placebo

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Clinical improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Histological improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.12 [0.05, 23.99]
1 study · 20 participants
Low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Systemic aminocaproic acid vs placebo

Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema

Systemic aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).

1 finding from 1 review

Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
RR 0.87 [0.57, 1.32]
1 study · 34 participants
Low

Topical aminocaproic acid vs placebo

Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical aminocaproic acid vs placebo

Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical aminocaproic acid vs placebo

Time to resolution of primary hemorrhage · people with traumatic hyphema

1 finding from 1 review

Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Low

Topical aminocaproic acid vs placebo

Secondary hemorrhage at any time point · people with traumatic hyphema

Topical aminocaproic acid showed no clear difference in secondary hemorrhage at any time point compared with placebo (low certainty).

1 finding from 1 review

Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
RR 0.48 [0.2, 1.1]
2 studies · 131 participants
Low

Topical aminocaproic acid vs placebo

Adverse effects: systemic hypotension · people with traumatic hyphema

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found